Richard B. Lanman

Richard Burnham Lanman is an American biotechnology entrepreneur, physician scientist, and naturalist.[1] His contributions relate to improving diagnosis and utilization of less invasive medical procedures,[2][3] most recently as Global Chief Medical Officer at Guardant Health, Inc., a precision oncology company that developed a blood test replacing repeat invasive tissue biopsies to sequence tumor DNA and improve cancer treatment selection.[4][5][6] Lanman has worked in five different medical specialties, oncology, cardiology, endocrinology, pulmonology, and psychiatry, as well as historical ecology, in which he has authored or co-authored over 100 peer-reviewed articles[7][8][9][10][11] and two book chapters.[3][12]

Rick Lanman
Born
Richard Burnham Lanman Jr.

(1955-03-10) March 10, 1955
Frankfurt am Main, Hesse, Germany
NationalityUnited States of America
EducationStanford University, B.S. 1977
Northwestern University School of Medicine, M.D. 1980
OccupationPhysician-scientist and Naturalist
Years active1978-present
Known forBiomarkers in Cardiovascular disease and Cancer, and Historical ecology
RelativesMartha Lee Hopkins Struever (mother)
Fritz Lanman (son)
James Lanman (son)
Medical career
ProfessionMedical Doctor
InstitutionsGuardant Health, Inc.
Veracyte, Inc.
diaDexus, Inc.
Atherotech, Inc.
San Jose Medical Group, Inc.
Kaiser Permanente
ResearchCancer genomics, Precision oncology, Cardiovascular Biomarkers, Thyroid cancer, Interstitial lung disease, Psychiatry, Ecology

Early life and education

Lanman was born at an U.S. Army Hospital in Frankfurt am Main, Hesse, Germany, in 1955. He is the son of American Indian art dealer and author Martha Lee Hopkins Lanman Struever and Lieutenant Richard Burnham Lanman Sr.[13] Lanman grew up in Munster, Indiana where his parents had a hardware store. At age 11, his father died from leukemia. Lanman graduated Phi Beta Kappa at Stanford University, with a B.S. in Chemistry in 1977.

After obtaining his M.D. from the Northwestern University School of Medicine in 1980, Lanman began his medical internship at Northwestern Memorial Hospital, then in July 1981 began another medical internship at the University of California San Francisco Moffit Hospital. From 1982 to 1985 he completed his residency in psychiatry at Langley Porter Psychiatric Institute, also at UCSF. He became a diplomate of the American Board of Psychiatry and Neurology in 1990. During medical school and residency, Lanman authored journal articles in cardiology and psychiatry,[14][15] including a book chapter.[12]

Career

Lanman began his medical career as an attending psychiatrist at Kaiser Permanente in Northern California in 1985. After two years of practice at Kaiser in Santa Clara County, he was appointed Chief of Psychiatry, and then, as Chief of Quality, encouraged adoption of less invasive procedures and improvements in diagnosis in other specialties, culminating in a book chapter he authored on variation in physician practice patterns and hospitalization rates for children with asthma across Kaiser's 14 hospitals in Northern California.[3]

Lanman moved from Kaiser Permanente to take a position as Chief Medical Officer and Sr. Vice President at San Jose Medical Group (SJMG), in San Jose, California from 1993 to 1995, managing over 130 employed physicians with a focus on medical quality and cost initiatives.[16][17][18][19] San Jose Medical Group was named the "most effective managed care medical group in the country" in 1996 by The Advisory Board Company, and Lanman educated other integrated delivery systems on reducing overall healthcare costs by focusing on medical quality improvement, especially hospitalization costs.[20]

In 1995, Lanman left physician practice management to start Adesso Healthcare Technology Services as Founder and Chief Executive Officer.[21][22] Adesso offered an alternative to a cost-cutting approach by health maintenance organizations (HMOs) that had been using primary care physicians as gatekeepers, limiting access to specialty physician care.[23] Under Adesso, patients could be referred to specialist physician networks, such as cardiologists or ophthalmologists, without preauthorization. In return the specialist networks contracted directly with health insurers, and instead of fee-for-service, the specialists were reimbursed utilizing severity-adjusted case rates for each episode of care.[2] This novel reimbursement model plus physician performance profiling, incentivized specialists to control costs via adoption of minimally invasive procedures and/or medical management over invasive procedures.[24] Adesso filed for an IPO in early 2000,[25] however, the public offering succumbed to the stock market crash that year.

Next, in 2000, Lanman joined Atherotech, Inc., a cardiovascular biomarker diagnostic company that had developed the Vertical Auto Profile- or VAP-expanded cholesterol and lipoprotein test, to improve prediction of risk of heart attack and stroke.[26][27][28] As Chief Medical Officer and Executive Vice President, Corporate Business Development, Lanman initiated studies investigating the technology's clinical utility,[29][30] and published validation studies on the VAP test's unique lipoprotein (a) (Lp(a)) cholesterol measurement and other lipoprotein biomarkers.[31] Atherotech was privately acquired by Behrman Capital.[32]

In 2005, Lanman joined a second preventive cardiology biomarker company, diaDexus, Inc., as Executive Vice President and Chief Medical Officer. DiaDexus developed a test for lipoprotein-associated phospholipase A2 (Lp-PLA2), the first FDA-cleared biomarker test to predict risk of stroke.[33][34] His published work established a clinical cutpoint[35] and contributed to a meta-analysis establishing elevated Lp-PLA2 levels as a risk for both coronary heart disease and stroke.[36] DiaDexus completed a reverse IPO via merger with VaxGen in 2010.[37]

After working in two companies to improve prediction of risk for cardiovascular events, Lanman joined Veracyte, Inc. in 2008 as Chief Medical Officer. Veracyte develops minimally invasive diagnostic tests utilizing genomics. Veracyte's initial genomics tests improved the diagnosis of thyroid nodules and lung nodules without resorting to surgery.[38][10] Lanman was also principal investigator in a study validating Veracyte's third genomics test to improve diagnosis of idiopathic pulmonary fibrosis versus other idiopathic interstitial pneumonias.[39] Veracyte, Inc. went public in October, 2013.[40]

In September 2014, Lanman joined Guardant Health, Inc. where he served as Global Chief Medical Officer.[6] Guardant's first diagnostic test, Guardant360® enabled sequencing of the DNA in patients’ advanced cancers with a simple blood test, as an aid in treatment selection for targeted therapy or immunotherapy without the need for repeat invasive tissue biopsies.[4] This non-invasive test was approved by Medicare to help identify targetable mutations in most solid tumor cancers in 2019.[41] Lanman also collaborated with National Cancer Institute-designated cancer centers to validate and test the clinical utility of two other Guardant products: GuardantOMNI™, a blood test that can predict response to immunotherapy in lung and colon cancer, and LUNAR, a test for early stage cancers and also for the early detection of cancer. Guardant Health went public in October, 2018.[42]

Lanman has also published on historical ecology, establishing novel physical evidence that the North American beaver (‘’Castor canadensis’’) was native to virtually all of California.[11][43][44] A 2018 book by environmental journalist Ben Goldfarb explored how a cancer geneticist ended up researching beaver and salmonids.[1] In early 2020 Lanman presented a scientific study based on ancient DNA sequencing of salmonid remains from archaeological excavations at Mission Santa Clara which extended the southern limit of historic spawning range of Chinook salmon, to San Jose, California.[45]

Lanman retired from Guardant Health on December 31, 2019. He continues his historical ecology research and publications, while also serving on the Board of Biolase, Inc., WeTree, Inc., and as an Advisor to Forward Medical, Inc. and Guardant Health, Inc.

Recognition

Lanman was selected as one of ten psychiatry residents across the country to be an American Psychiatric Association Leadership Fellow in 1982, and then selected from over 400 psychiatry residents to serve on the American Psychiatric Association Board of Trustees from 1983 to 1985.[46]

Lanman serves on the Board of Directors of Biolase, Inc, a dental laser manufacturer and the Santa Clara County Resource Conservation District, and is an advisor to Forward Medical, Inc., Compass Technology Partners, a venture capital firm, and Guardant Health, Inc.

Personal life

Lanman married Alanna Purcell in 1978 and they raised five sons in Los Altos, California.

See also

References
  1. Ben Goldfarb (2018). Eager: The Surprising, Secret Life of Beavers and Why They Matter. Chelsea Green Publishing. pp. 135–141. ISBN 9781603587402. Retrieved January 6, 2019.
  2. L. Page (May 15, 2000). "Fee for Episode". American Medical News. pp. 13–14.
  3. Lanman R (1994). Horn SD; Hopkins DSP (eds.). Improving Pediatric Asthma Care in a Health Maintenance Organization, in Clinical Practice Improvement: A New Technology for Developing Cost-Effective Quality Health Care. New York: Faulkner & Gray, Inc. pp. 169–174. ISBN 9781881393252.
  4. João Medeiros (February 5, 2017). "Marcus Krause's lung cancer wouldn't stop growing. Then he took a new kind of blood test". Wired UK. Retrieved February 1, 2020.
  5. Richard Harris (December 16, 2016). "When Genetic Tests Disagree About Best Option For Cancer Treatment". National Public Radio (NPR). Retrieved February 3, 2020.
  6. Anna Czene (December 11, 2019). "Study Shows Only 40 Percent of Patients with Metastatic Colon Cancer Receive Guideline-Recommended Biomarker Testing". Barron's. Retrieved February 20, 2020.
  7. T. P. Slavin, K. C. Banks, D. Chudova, G. R. Oxnard, J. I. Odegaard, R. J. Nagy, K. W. K. Tsang, S. L. Neuhausen, S. W. Gray, M. Cristofanilli, A. A. Rodriguez, A. Bardia, B. Leyland-Jones, M. F. Janicek, M. Lilly, G. Sonpavde, C. E. Lee, R. B. Lanman, F. Meric-Bernstam, R. Kurzrock, J. N. Weitzel (December 10, 2018). "Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing". Journal of Clinical Oncology. 36 (35): 3459–3465. doi:10.1200/JCO.18.00328. PMC 6286162. PMID 30339520.CS1 maint: uses authors parameter (link)
  8. C. M. Blakely, T. B. K. Watkins, W. Wu, B. Gini, J. J. Chabon, C. E. McCoach, N. McGranahan, G. A. Wilson, N. J. Birkbak, V. R. Olivas, J. Rotow, A. Maynard, V. Wang, M. A. Gubens, K. C. Banks, R. B. Lanman, A. F. Caulin, J. St John, A. R. Cordero, P. Giannikopoulos, A. D. Simmons, P. C. Mack, D. R. Gandara, H. Husain, R. C. Doebele, J. W. Riess, M. Diehn, C. Swanton, T. G. Bivona (November 6, 2017). "Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers". Nature Genetics. 49 (12): 1693–1704. doi:10.1038/ng.3990. PMC 5709185. PMID 29106415.CS1 maint: uses authors parameter (link)
  9. J. B. Muhlestein, H. T. May, J. R. Jensen, B. D. Horne, R. B. Lanman, F. Lavasani, R. L. Wolfert, R. R. Pearson, H. D. Yannicelli, J. L. Anderson (July 18, 2006). "The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study". Journal of the American College of Cardiology. 48 (2): 396–401. doi:10.1016/j.jacc.2006.05.009. PMID 16843192.CS1 maint: uses authors parameter (link)
  10. E. K. Alexander, G. C. Kennedy, Z. W. Baloch, E. S. Cibas, D. Chudova, J. Diggans, L. Friedman, R. T. Kloos, V. A. LiVolsi, S. J. Mandel, S. S. Raab, J. Rosai, D. L. Steward, P. S. Walsh, J. I. Wilde, M. A. Zeiger, R. B. Lanman, B. R. Haugen (August 23, 2012). "Preoperative diagnosis of benign thyroid nodules with indeterminate cytology". New England Journal of Medicine. 367 (8): 705–715. doi:10.1056/NEJMoa1203208. PMID 22731672.CS1 maint: uses authors parameter (link)
  11. James CD; Lanman RB (2012). "Novel physical evidence that beaver historically were native to the Sierra Nevada". California Fish and Game. 98 (2): 129–132. Retrieved January 6, 2019.
  12. Lanman RB; Pardes H; Benedek EP; Rink PJ; Wiener JM (1989). Talbott JA (ed.). Reorganizing for the Future, in Future Directions for Psychiatry. Washington, D.C.: American Psychiatric Press, Inc. pp. 172–180. ISBN 9780890422151.
  13. Robert Bauver (2017). "Memories of Marti: In Memoriam" (PDF). ATADA News. Antique Tribal Art Dealer Association. pp. 8–9. Retrieved January 27, 2018.
  14. Ogunro EA; Lanman RB; Spencer JR; Ferguson AG; Lesch M (November 1979). "Degradation of canine cardiac myosin and actin by cathepsin D isolated from homologous tissue". Cardiovasc Research. 13 (11): 621–629. doi:10.1093/cvr/13.11.621. PMID 42492.
  15. H. Levenson; R. Lanman; M. Rankin (1982). "Traumatic war neurosis and phenelzine". Archives of General Psychiatry. 39 (11): 1345. doi:10.1001/archpsyc.1982.04290110093018. PMID 7138237.
  16. "From Kaiser to San Jose". San Francisco Business Times. October 4, 1993. p. 19.
  17. Physician-Driven Integration: A response to the Corporatization of Medicine (PDF) (Report). Philadelphia, Pennsylvania: American College of Physicians. 1996.
  18. James C. Robinson; Lawrence P. Casalino (December 21, 1995). "The Growth of Medical Groups Paid through Capitation in California". New England Journal of Medicine. 333 (25): 1684–1687. doi:10.1056/NEJM199512213332506. PMID 7477222.
  19. Capitation in California: A Study of Physician Organizations Managing Risk. Maurice Penner. 1997. p. 44. ISBN 978-1-56793-051-1.
  20. Philip M. Mack (July 1, 1996). "A Capital Idea". California Medicine. 3 (7). San Francisco, California: California Medicine Publishing, Inc. pp. R3–R14.
  21. Wendy Sheanin (August 8, 1995). "People in Business". SFGate/San Francisco Chronicle.
  22. Peter Sinton (February 11, 1998). "Venture Money Pot Swells / Information technology firms draw bulk of it". San Francisco Chronicle.
  23. Chris Rauber (December 17, 1995). "Medical services firm to assist specialists' operations". San Francisco Business Times. p. 9.
  24. Jeff Goldsmith (December 2000). "The Internet And Managed Care: A New Wave Of Innovation". Health Affairs. 19 (6): 42–56. doi:10.1377/hlthaff.19.6.42. PMID 11192421.
  25. Chris Rauber (August 10, 1997). "Adesso looks toward national expansion". San Francisco Business Times.
  26. Vanessa Gisquet (September 30, 2004). "Blood Feud". Forbes. Retrieved February 6, 2020.
  27. Anne Paxton (July 1, 2002). "One option for a more complete profile". CAP Today. Retrieved February 2, 2020.
  28. Krishnaji R. Kulkarni (December 2006). "Cholesterol profile measurement by vertical auto profile method". Clinics in Laboratory Medicine. 26 (4): 787–802. doi:10.1016/j.cll.2006.07.004. PMID 17110240.
  29. Joshi PH; Khokhar AA; Massaro JM; Lirette ST; Griswold ME; Martin SS; Blaha MJ; Kulkarni KR; Correa A; D'Agostino RB Sr.; Jones SR; Toth PP (April 2016). "Remnant lipoprotein cholesterol and incident coronary heart disease: The Jackson Heart and Framingham Offspring Cohort Studies". Journal of the American Heart Association. 5 (5): 1–10. doi:10.1161/JAHA.115.002765. PMC 4889167. PMID 27130348.
  30. Paul T. Williams; Xue-Qiao Zhao; Santica M.; Marcovina, James D.; Otvos, B.; Greg Brown; Ronald M. Krauss (April 2014). "Comparison of four methods of analysis of lipoprotein particle subfractions for their association with angiographic progression of coronary artery disease". Atherosclerosis. 233 (2): 713–720. doi:10.1016/j.atherosclerosis.2014.01.034. PMC 3990359. PMID 24603218.
  31. R. B. Lanman (2004). "VAP - A Better Cholesterol Test". Journal of Clinical Ligand Assay. 27: 97–100.
  32. Ben Piper (January 13, 2011). "Atherotech acquired by Behrman Capital". Birmingham Business Journal. Retrieved January 31, 2020.
  33. Karen Lusky (July 2008). "New clue for predicting stroke risk: Lp-PLA2". CAP Today.
  34. FDA Decision Summary: 510(k) Substantial Equivalent Determination (PDF) (Report). December 15, 2005.
  35. R. B. Lanman; R. L. Wolfert; J. K. Fleming; A. S. Jaffe; W. L. Roberts; G. R. Warnick; J. P. McConnell (2006). "Lipoprotein-associated phospholipase A2: review and recommendation of a clinical cut point for adults". Preventive Cardiology. 9 (3): 138–143. doi:10.1111/j.1520-037X.2006.05547.x. PMID 16849876.
  36. Thompson A; Gao P; Orfei L; Watson S; Di Angelantonio E; Kaptoge S; Gao P; Orfei L; Watson S; Di Angelantonio E; Kaptoge S; Ballantyne C; Cannon CP; Criqui M; Cushman M; Hofman A; Packard C; Thompson SG; Collins R; Danesh J (May 2010). "Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies". Lancet. 375 (9725): 1536–44. doi:10.1016/S0140-6736(10)60319-4. PMC 2864403. PMID 20435228.
  37. "VaxGen to Acquire diaDexus in a Stock-for-Stock Merger". FierceBiotech. April 14, 2010.
  38. "Veracyte, Inc. developed diagnostics for thyroid and non-small cell lung cancer". iCloudNewswire. July 4, 2019.
  39. "New tissue test for idiopathic pulmonary fibrosis changes the diagnostic game". PulmCCM. December 6, 2019.
  40. Mark Hollmer (October 13, 2013). "Veracyte goes public, raises $65M and gains on Day 1". FierceBiotech.
  41. "Guardant Health Liquid Biopsy Test Gets Expanded Medicare Coverage for Solid Tumors". GenomeWeb. December 19, 2019.
  42. Emma Court (October 14, 2018). "Guardant Health IPO: 5 things to know about the startup that wants to detect cancer early". MarketWatch.
  43. Lanman RB; Perryman H; Dolman B; James CD (2012). "The historical range of beaver in the Sierra Nevada: a review of the evidence". California Fish and Game. 98 (2): 65–80. Retrieved January 6, 2019.
  44. Lanman CW; Lundquist K; Perryman H; Asarian JE; Dolman B.; Lanman RB; Pollock MM (2013). "The historical range of beaver (Castor canadensis) in coastal California: an updated review of the evidence". California Fish and Game. 99 (4): 193–221. Retrieved January 6, 2019.
  45. Richard B. Lanman, MD (February 1, 2020). "Novel Physical Evidence of the Historical Nativity of Chinook Salmon "Oncorhynchus tshawytscha" in the Guadalupe River Watershed of Santa Clara County, California". Salmonid Restoration Foundation. Retrieved February 2, 2020.
  46. "Richard B. Lanman Jr., M.D.". Psychiatric News – Newspaper of the American Psychiatric Association. XX (2). January 18, 1985.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.